ArticleJournal of personalized medicine2026
Real-World Evidence That As-Needed Dosing with Bimekizumab in Patients with Psoriasis Is Safe and Effective over Time.
Carlota Abbad-Jaime De Aragón, María Davo-Mogica, Pablo de la Cruz-Anaya, Emilio Berna-Rico, Inés Díaz-Ruiz, Inés Perales-Sánchez, Nicholas D Brownstone, Pedro Jaén, Lluis Puig, Andrew Blauvelt and 1 more
Abstract read
In one paragraphArticle in Journal of personalized medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Carlota Abbad-Jaime De AragónDepartment of Dermatology, Hospital Universitario Ramón y Cajal, Instituto Ramon Y Cajal de Investigación Sanitaria (IRYCIS), 28034 Madrid, Spain.ORCID 0000-0002-5587-1204 María Davo-MogicaInflammatory Disease and Psoriasis Unit, Grupo Pedro Jaén, 28006 Madrid, Spain.
Pablo de la Cruz-AnayaDepartment of Dermatology, Hospital Universitario Ramón y Cajal, Instituto Ramon Y Cajal de Investigación Sanitaria (IRYCIS), 28034 Madrid, Spain.
Emilio Berna-RicoDepartment of Dermatology, Hospital Universitario Ramón y Cajal, Instituto Ramon Y Cajal de Investigación Sanitaria (IRYCIS), 28034 Madrid, Spain.ORCID 0000-0003-0348-5421 Inés Díaz-RuizFaculty of Medicine, Universidad Francisco de Vitoria, 28223 Madrid, Spain.
Inés Perales-SánchezDepartment of Vascular Physiopathology, Hospital Nacional de Parapléjicos, Servicio de Salud de Castilla-La Mancha (SESCAM), 45071 Toledo, Spain.
Nicholas D BrownstoneDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Pedro JaénDepartment of Dermatology, Hospital Universitario Ramón y Cajal, Instituto Ramon Y Cajal de Investigación Sanitaria (IRYCIS), 28034 Madrid, Spain.
Lluis PuigDepartment of Dermatology, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU), Universitat Autònoma de Barcelona, 08041 Barcelona, Spain.ORCID 0000-0001-6083-0952 Alvaro González-CanteroDepartment of Dermatology, Hospital Universitario Ramón y Cajal, Instituto Ramon Y Cajal de Investigación Sanitaria (IRYCIS), 28034 Madrid, Spain.
Funding
Fundacion Pedro Jaen psoriasis research
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
as-neededbimekizumaboff-labelon-demandpsoriasis
Identifiers
PMID42188329
PMCPMC13208962
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390